Roche Adds Another Neuro Alliance, Inking R&D Pact With RNA-Editing Startup Ascidian

Posted
Ascidian Therapeutics’ technology edits RNA to treat inherited disorders. While the startup’s lead internal program is for the retinal disorder Stargardt disease, its new R&D alliance with Roche will focus on developing RNA-editing therapies for neurological indications. The post Roche Adds Another Neuro Alliance, Inking R&D Pact With RNA-Editing Startup Ascidian appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Daily, Pharma, Startups, Ascidian Therapeutics, biopharma nl, Boston, deals, neurological disorders, rna therapeutics, Roche